Clinical trial Recruiting at 1 site Observational Ages 18 and up

Predicting effectiveness of robotic treatment for neurological diseases

Official title: Clinical and Instrumental Treatment's Predictors in Subjects With Neurological Diseases Using G-EO Robotic System: an Observational Longitudinal Study

Run by Fondazione Don Carlo Gnocchi ETS · NCT05493514 · Data updated 2026-11-12

This study is testing how well robotic treatment can help people with neurological diseases like Multiple Sclerosis, Stroke, and Parkinson's by looking at different factors that might affect their recovery.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment260 (estimated)
SponsorFondazione Don Carlo Gnocchi ETS
Academic / other
Locations1 site (Milan)
StatusRecruiting
StartedMay 13, 2022
Main results expectedApril 1, 2027
Study endsApril 1, 2027
Registry record updatedAugust 9, 2022
Trial IDNCT05493514 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older diagnosed with Multiple Sclerosis, Parkinson Disease, Stroke, or acquired brain injury who can walk at least 10 meters.

Probably not a fit

Patients with severe limitations in joint range of motion or other medical conditions that compromise walking may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop a statistical model to predict the effectiveness of robotic treatment using the G-EO system in patients with neurological diseases such as Multiple Sclerosis, Stroke, and Parkinson Disease. The study will assess various clinical and instrumental characteristics of participants to identify predictors of treatment success. Participants will undergo robotic-assisted gait training, and their responses will be analyzed to understand which factors contribute to better outcomes. The findings could help tailor robotic therapies to individual patient needs.

Why it matters

Potential benefit: If successful, this study could enhance the effectiveness of robotic treatments for patients with neurological disorders by identifying who will benefit most.

How similar studies have gone: While robotic rehabilitation is a growing field, this specific approach to predicting treatment effectiveness using statistical modeling is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosis of Multiple Sclerosis, Parkinson Disease, Stroke or acquired brain injury
* Minimum number of sessions: 10 sessions with the GEO system
* Minimum frequency of sessions: 2 per week
* Age ≥ 18 years
* Ability to walk for at least 10 meters, also with aid
* Indication of robotic treatment in the therapeutic plan
* Body size suitable for the robotic device
* ability to maintain verticality for 7 minutes;
* ability to maintain the sitting position without support for 30 seconds;

Exclusion Criteria:

* severe limitations of articular range of motion;
* medical problems compromising walking (e.g. fractures, pain, severe osteoporosis or severe spasticity);
* Presence of skin lesions in the areas of contact with the device;
* Presence of seizures that may be triggered by the use of the G-EO system.

Where it's running

  • Don Gnocchi Foundation
    Milan, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.